Reclassification of Five BRCA1/2 Variants with Unknown Significance Using Complex Functional Study
Authors:
Open Access
- 8 February 2022
- journal article
- research article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 54 (4) , 970-984
Abstract
Purpose While BRCA1/2 genes are commonly investigated, variants of unknown significance (VUS) and variants with potential splice effect are still being detected and they represent a substantial challenge in genetic counseling and therapy.Materials and Methods Out of genetically tested 3,568 hereditary breast and ovarian cancer probands five, functionally notinvestigated variants with potential splice-modifying effect were subjected to functional characterization. Transcript-level analysis on peripheral blood-derived RNA of the carriers was performed to test aberrant splicing. The completeness of the aberrant splicing event was also studied, existence and extent of nonsense-mediated decay was even addressed. Clinical and phenotype data, pedigree and co-segregation analyses were also done. Locus-specific loss of heterozygosity (LOH) in tumor tissues was additionally tested.Results In case of the BRCA1:c.4484+4dupA and the BRCA1:c.5407-10G>A variants functional results allowed us to reclassify them from VUS into likely pathogenic category. BRCA1:c.4358-31A>C, by producing incomplete aberrant splicing, was highlighted as strong VUS, but in lack of other supporting evidence, re-categorization was not possible. The likely pathogenic assertion of previously not reported BRCA2:c.8487G>T was reinforced based on its spliceogenic property and tumor LOH, while BRCA2:c.793G>A failed to present aberrant splicing in spite of suggestive predictions, which altered its original VUS evaluation into likely benign class.Conclusion We presented molecular and clinical evidence for reclassification of four out of five BRCA1/2 variants. Both up- and down-classification harbour important clinical significance. Patients carrying re-classified pathogenic variants in the future will not be dropped out from medical surveillance, preventive measures, treatment and predictive family screening in relatives at risk.Keywords
Funding Information
- Hungarian Thematic Excellence Programme (TKP2020-NKA-26)
- Development and Innovation Office (NKFI FK 135065)
This publication has 29 references indexed in Scilit:
- Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithmsHuman Molecular Genetics, 2016
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variantsHuman Mutation, 2012
- Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: Variant reclassification and surgical decisionsGenetics in Medicine, 2011
- High prevalence of germline STK11mutations in Hungarian Peutz-Jeghers Syndrome patientsBMC Medical Genetics, 2010
- cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutationMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009
- Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigeneJournal of Medical Genetics, 2008
- Management of an Inherited Predisposition to Breast CancerNew England Journal of Medicine, 2007
- Integrated Evaluation of DNA Sequence Variants of Unknown Clinical Significance: Application to BRCA1 and BRCA2The American Journal of Human Genetics, 2004
- Defects in Pre-mRNA Processing as Causes of and Predisposition to DiseasesDNA and Cell Biology, 2002